Event Details

Accelerating Cell and Gene Therapy Adoption: From Proof of Concept to Standard of Care

Immatics will be part of the virtual Annual Meeting of the International Society Cell & Gene Therapy - ISCT 2020 Paris Virtual. The program on May 28-29 will be accessible remotely and on-demand to provide critical and timely education to Accelerate Cell & Gene Therapy Adoption: From Proof of Concept to Standard of Care.

Join VP Ali Mohamed in a pre-recorded tutorial and learn more about Immatics’ QC testing strategies to improve manufacturing turnaround time and our TCR-based cancer immunotherapies.

Available from Thursday, May 28, until May 26, 2021

Advancing QC Testing for Cell and Gene Therapy Products

• The successful development and commercialization of Cell and Gene Therapy products opened a hope for patients with urgent medical needs and opened a door for a new era of modern medicine.
• However, the manufacturing of C&GT products is very complex and they have to be released in a short timeframe. These are high value products, available in limited quantity that should be controlled employing complex set of tests in order to ensure identity, safety and potency.
• The current microbiological compendial methods like sterility and mycoplasma testing are not adapted to these products. During this tutorial, industry experts will address the QC Testing Strategies to Improve Manufacturing Turnaround Time, the bioMérieux Microbiology Testing Solutions to Increase Operational Efficiency and Improve Patient Safety and will discuss How to Make Rapid Testing Mainstream for ATMPs.

Presenters: Ali Mohamed, Immatics (USA); Félix A. Montero Julian, bioMerieux (FRA); Dominic Wall, Peter MacCallum Cancer Centre (AUS)

More information on the ISCT 2020 – Paris Virtual can be found here.